Genprex Signs Exclusive License To Additional Diabetes Technology With The University Of Pittsburgh
Portfolio Pulse from Happy Mohamed
Genprex, Inc. (NASDAQ: GNPX) has signed an exclusive license agreement with the University of Pittsburgh for a gene therapy for both Type 1 and Type 2 diabetes. The therapy uses the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter. The newly licensed technology is based on the same general gene therapy approach under Genprex's original license. Preclinical data shows significant decreases in insulin requirements, increases in c-peptide levels, and improvements in glucose tolerance.
July 18, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's exclusive license agreement with the University of Pittsburgh for a gene therapy for diabetes could potentially strengthen its product portfolio and increase its market share in the diabetes treatment market.
The exclusive license agreement allows Genprex to potentially develop a new gene therapy for diabetes, which could strengthen its product portfolio and increase its market share in the diabetes treatment market. The preclinical data showing significant improvements in insulin requirements, c-peptide levels, and glucose tolerance also suggests that the therapy could be effective, which could further boost Genprex's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100